

R&D Pipeline

antibody
 protein
 small molecule
 © New Molecular Entity
 Updated since Dec. 31, 2020
 Updated since Mar. 31, 2021

Nephrology

As of June 30, 2021

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KHK7580 Evocalcet Oral	Calcimimetic	Secondary Hyperparathyroidism	CN Asia						[Mitsubishi Tanabe Pharma] product name in Japan: Orkedia
©RTA 402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	Diabetic Kidney Disease	JP						[Reata]
		Autosomal Dominant Polycystic Kidney Disease	JP						
KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Preeclampsia	JP						[In-House] product name in Japan:Acoalan
KHK7791 Tenapanor Oral	NHE3 Inhibitor	Hyperphosphatemia in Patients on Dialysis	JP						[Ardelyx]

Oncology

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Mycosis Fungoides and Sézary Syndrome	SA						[In-House] POTELLIGENT® product name in Japan, U.S. and Europe: Poteligeo
			AU						
			CH KR						
			CN						
			CA KW						
©KHK2375 Entinostat Oral	HDAC Inhibitor	Breast Cancer	JP						[Syndax]
KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony- Stimulating Factor	Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Allogeneic Blood Stem Cell Transplantation	JP						[Kirin-Amgen] product name in Japan:G-Lasta
		Automated Injection Device for Decreasing the Incidence of Febrile Neutropenia in Patients Receiving Cancer Chemotherapy	JP						
©KHK2455 Oral	IDO1 Inhibitor	Solid Tumor	NA						[In-House] Combination with KW-0761
		Urothelial carcinoma	NA						[In-House] Combination with avelumab
			Europe						
©ME-401 Zandelisib Oral	PI3Kδ Inhibitor	Indolent B-cell Non-Hodgkin's Lymphoma	JP						[MEI Pharma]
		B-cell malignancies	NA						
		Follicular Lymphoma and Marginal Zone Lymphoma	NA Europe Asia Oceania						

Immunology/Allergy

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Ankylosing Spondylitis	TW						[Kirin-Amgen] product name in Japan: Lumicef
		Systemic Sclerosis	JP						
		Palmoplantar Pustulosis	JP						
©KHK4083 Injection	Anti-OX40 Fully Human Antibody	Atopic Dermatitis	JP NA Europe						[In-House] POTELLIGENT® Human Antibody-Producing Technology

※ Since the development of ASKP1240 for Recurrence of Focal Segmental Glomerulosclerosis (FSGS) in de novo kidney transplant recipients was discontinued, the relevant information was deleted from this table.

R&D Pipeline

antibody
 protein
 small molecule
 © New Molecular Entity
 Updated since Dec. 31, 2020
 Updated since Mar. 31, 2021

Central Nervous System

As of June 30, 2021

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KW-6002 Istradefylline Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	Europe						[In-House] product name in Japan: Nourias, product name in U.S.: Nourianz
©KW-6356 Oral	Adenosine A _{2A} Receptor Antagonist/Inverse Agonist	Parkinson's Disease	JP						[In-House]
©KHK6640 Injection	Anti-Amyloid Beta Peptide Antibody	Alzheimer's Disease	JP Europe						[Immunas Pharma]

※ Since the development of KW-0761 for HTLV-1 associated myelopathy (HAM) was discontinued, the relevant information was deleted from this table.

Other

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH)	SG SA						[In-House] Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU product name in Japan, U.S. and Europe: Crystvita
			CN BH						
			AU						
		TL MY							
		Tumor Induced Osteomalacia (TIO)	CN						
			Europe						
CA									
AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia Who Have Had an Inadequate Response to Conventional Therapy	Asia						[Kirin-Amgen] product name in Japan: Romiplate
		Immune Thrombocytopenia (ITP)	CN						
		Aplastic Anemia Who Were Previously Untreated with Immunosuppressive Therapy	JP Asia						
KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Europe						[In-House] product name in Japan: Acoalan
KHK4951		Wet Age-Related Macular Degeneration	JP						[In-House]